Abstract #0091

MRI-US Fused Targeted Prostate Biopsy Detects Clinically Significant Cancer in Active Surveillance Patients Better Than 12 Core Random Biopsy with Less Than 4 Cores

Michael Da Rosa¹,², Laurent Milot¹,³, Linda Sugar,³⁴, Danny Vesprini,³⁵, Hans Chung,³⁵, Andrew Loblaw,³⁵, Laurence Klotz,³⁶, Masoom A. Haider¹,³

¹Department of Medical Imaging, University of Toronto, Toronto, ON, Canada; ²Institute of Medical Science, University of Toronto, Toronto, ON, Canada; ³Sunnybrook Health Sciences Centre, Toronto, ON, Canada; ⁴Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; ⁵Radiation Oncology, University of Toronto, Toronto, ON, Canada; ⁶Division of Urology, University of Toronto, Toronto, ON, Canada

The purpose of this prospective study was to determine the ability of an MRI-US fusion biopsy system to detect clinically significant (CS) disease in active surveillance (AS) patients compared to random transrectal ultrasound (R-TRUS) guided biopsy (bx). Multiparametric MRI prospectively identified up to 4 suspicious targets in each patient. Biopsy was performed using an MRI-ultrasound navigation system (UroNav, Philips Healthcare). MRI-US fusion biopsy detected more CS cancers with fewer biopsy cores than random biopsy in AS patients. In addition, MRI in AS patients has a high negative predictive value for the presence of CS disease on subsequent biopsy.